edoc

Advancing drug innovation for neglected diseases-criteria for lead progression

Nwaka, S. and Ramirez, B. and Brun, R. and Maes, L. and Douglas, F. and Ridley, R.. (2009) Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Neglected Tropical Diseases, Vol. 3, H. 8 , e440.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A5843131

Downloads: Statistics Overview

Abstract

The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Access to technologies, resources, and strong management as well as clear compound progression criteria are factors in the successful implementation of any collaborative drug discovery effort. We discuss how some of these factors have impacted drug discovery for tropical diseases within the past four decades, and highlight new opportunities and challenges through the virtual North-South drug discovery network as well as the rationale for greater participation of institutions in developing countries in product innovation. A set of criteria designed to facilitate compound progression from screening hits to drug candidate selection is presented to guide ongoing efforts
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Parasite Chemotherapy (Mäser)
UniBasel Contributors:Brun, Reto
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Library of Science
ISSN:1935-2727
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:14 Sep 2012 07:17
Deposited On:14 Sep 2012 06:41

Repository Staff Only: item control page